StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) stock

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)

Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –

Pacira BioSciences, Inc. grew revenue 5.7% to $746.16M over the twelve months to Jun 30, 2026. Free cash flow was $179.52M, up 53.3% from a year earlier. At the latest close the market valued the company at $1.45B, 104.2 times its earnings.

Revenue
$746.16M
+5.7% vs. a year earlier
Operating income
$19.87M
TTM Q2 2026
Free cash flow
$179.52M
+53.3% vs. a year earlier
EPS, diluted
$0.35
TTM Q2 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$1.45B
P/E ratio
104.2
Price to sales
1.95
Price to book
2.16
Dividend yield
–
Free cash flow yield
12.34%

Fundamentals

Revenue
$746.16M
Net income
$14.64M
EPS, diluted
$0.35
Free cash flow
$179.52M
Book value per share
$16.67
Diluted shares
40M

Trading

Next earnings
Q3 FY2026, expected soon
Previous close
$36.48
Open
$36.48
Day's range
$36.48 – $36.48
Average volume (20 days)
1,070,425
Index membership
S&P SmallCap 600, Russell 2000, Russell 3000
52-week range
$18.80 – $36.66
RSI (14 days)
82.9
Volatility (1 year)
56.4%
Relative volume
1.61×

On 2 of our idea lists: Buyback cannibals, Shareholder yield

Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2011, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodPCRXS&P 500DifferencePCRX per yearS&P 500 per year
1 month+0.4%-4.0%+4.4 pts
3 months+57.0%-5.0%+61.9 pts
Year to date+41.0%+8.2%+32.7 pts
1 year+52.8%+11.2%+41.5 pts
3 years+30.8%+68.5%−37.7 pts+9.4%+19.0%
5 years-35.8%+67.3%−103.0 pts-8.5%+10.8%
10 years-0.2%+291.6%−291.8 pts-0.0%+14.6%

Fifteen years at a glance

Fiscal years 2011 to 2025 and trailing twelve months, USD

Revenue

$746.16M+5.7% YoY

Gross profit

$591.01M+7.1% YoY

Operating income

$19.87M

Net income

$14.64M

EPS, diluted

$0.35

Free cash flow

$179.52M+53.3% YoY
Reported periodTrailing twelve months

Press releases

Releases Pacira BioSciences filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Pacira BioSciences

Pharmaceutical Preparations

Pacira BioSciences develops and commercializes non-opioid pain therapies for patients undergoing surgical procedures or managing chronic joint conditions. The company provides three primary commercial products: EXPAREL, a long-acting injectable local analgesic for postsurgical pain; ZILRETTA, an extended-release corticosteroid injection for osteoarthritis knee pain; and iovera, a handheld cryoanalgesia device that administers targeted cold temperatures to relieve nerve pain without drugs. Its therapies serve surgical patients, including adult and pediatric populations, as well as individuals suffering from osteoarthritis and chronic musculoskeletal pain.

Company profile, executives and history

Pacira BioSciences stock: common questions

What is Pacira BioSciences's stock price?

PCRX closed at $36.48 on Nov 17, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $18.80 and $36.66.

What is Pacira BioSciences's market cap?

Pacira BioSciences was worth $1.45B at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is PCRX's P/E ratio?

PCRX trades at 104.2 times earnings, based on diluted earnings per share of $0.35 over the twelve months to Jun 30, 2026.

How much revenue does Pacira BioSciences make?

Pacira BioSciences reported revenue of $746.16M for the twelve months to Jun 30, 2026, up 5.7% from a year earlier.

Does Pacira BioSciences pay a dividend?

No. Pacira BioSciences has not paid a cash dividend over the last twelve months.

When does Pacira BioSciences report earnings next?

Pacira BioSciences's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.

How has PCRX stock performed over the past year?

Including dividends, PCRX returned +52.8% over the past year, against +11.2% for the S&P 500.

How many PCRX shares are sold short?

3M shares were sold short at the latest FINRA report, 8.94% of the float, or 3.9 days of average trading volume.

Who are Pacira BioSciences's competitors?

Companies most similar to Pacira BioSciences by business, industry and size include RARE, COLL, ACAD, IONS, MIRM.

See a number that looks wrong?